Competition Related Topics 
Fierce Pharma
DECEMBER 1, 2023
Turkish authorities have launched an investigation into 19 pharmaceutical companies to probe whether their operations violated the country’s competition law, the Turkish Competition Authority discl | The companies, which include Pfizer, J&J, Sanofi, AbbVie, AstraZeneca, Merck and others are being probed for potentially violating Turkish competition (..)
MedCity News
SEPTEMBER 9, 2024
It explained that there is low competition among PBMs and high vertical integration with payers. The post AMA Report Details Low Competition in PBM Market appeared first on MedCity News. The American Medical Association released a new report on Monday on pharmacy benefit managers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 3, 2024
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, | Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the (..)
Fierce Pharma
MARCH 10, 2023
Pfizer hopes to nose out competition with approval for new migraine nasal spray Zavzpret kdunleavy Fri, 03/10/2023 - 10:22
Advertisement
Why are buyer-facing teams struggling and what can be done about it? Today’s buying experience is extremely challenging to navigate––with a plethora of choices, easy access to research, and competing (often contradictory) voices chiming in. Buyers struggle with being overwhelmed, indecision, and trusting the information that’s presented to them.
Fierce Pharma
OCTOBER 19, 2023
In the race for leadership in the treatment of early-stage non-small cell lung cancer (NSCLC), Bristol Myers Squibb has put up trial data that look competitive to those from Merck’s Keytruda. | But a key debate remains unsettled.
MedCity News
SEPTEMBER 16, 2024
The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News. Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020.
Advertiser: ZoomInfo
Longer sales cycles. Larger buying committees. Slow-moving compliance reviews. Every go-to-market team knows the frustrations that come from a drawn-out sales process. How can you speed it up? By building a modern GTM motion that uses data, automation, and proven best practices to unlock insights, engage customers, and win faster.
Advertiser: ZoomInfo
In this guide, we’ll walk through how streaming real-time intent data can supercharge your ABM strategy, including: How streaming real-time intent works The benefits of real-time intent in your ABM strategy How you can box out the competition
Advertiser: ZoomInfo
In today’s competitive marketplace, doing so is harder than ever. As a recruiter, your goal is to place the right candidates at the right jobs or into ideal accounts.
Advertiser: ZoomInfo
Intensifying competition. Longer sales cycles. Increasingly discerning buyers. More meetings. Economic uncertainty. Go-to-market teams of every size, in every industry, are grappling with these challenges firsthand. Thankfully, there’s an answer.
Advertiser: ZoomInfo
That means placing the right people in the right roles can be the difference between your business growing or stagnating — and the competition is getting fierce. Good people are the foundation of any organization.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks.
Expert insights. Personalized for you.
276 
Let's personalize your content